Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis.

p73 and p63 are recently cloned genes that share considerable structural and functional homologies with the p53 tumor suppressor gene. These genes, unlike p53, express multiple mRNA isoforms with variable biologic functions, and their suppressor nature has yet to be confirmed. To determine the interrelationship between these genes in the tumorigenesis of head and neck squamous carcinoma (HNSC), we performed immunohistochemical analyses of their protein products and compared the data with clinicopathologic parameters in 38 patients. In histologically normal epithelium, p53 and p73 showed similar basal and/or parabasal expression, but that of p53 was weaker and discontinuous. p63 staining was noted in more suprabasal cellular layers and was stronger. In dysplasias, all three markers manifested variable but gradual increase in extent and intensity of cellular expression with histologic progression. In carcinomas, p63 was the most frequently expressed (94.7%), followed by p73 (68.4%) and p53 (52.6%). Significant statistical correlation was noted only between p63 and p73 expressions (P =.04). Although no statistical correlation was found between p53 and p63 or p73, p53-negative tumors overexpressed either p63 or p73. p73 expression was associated with distant metastasis and perineural/vascular invasion. Our study indicates that (1) p63 and p73 expression may represent an early event in HNSC tumorigenesis, (2) the lack of correlation between p73 or p63 and p53 expression suggests an independent and/or compensatory functional role, (3) p73 expression may play a part in HNSC progression, and (4) p73 and p63 may function as oncogenes in the development of these tumors.

[1]  G. Viale,et al.  p63, a p53 Homologue, Is a Selective Nuclear Marker of Myoepithelial Cells of the Human Breast , 2001, The American journal of surgical pathology.

[2]  S. Lippman,et al.  p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. , 2001, Carcinogenesis.

[3]  H. Kato,et al.  Transcriptional dysregulation of the p73L / p63 / p51 / p40 / KET gene in human squamous cell carcinomas: expression of Δ Np73L, a novel dominant-negative isoform, and loss of expression of the potential tumour suppressor p51 , 2001, British Journal of Cancer.

[4]  G. Blandino,et al.  From p63 to p53 across p73 , 2001, FEBS letters.

[5]  X. Zeng,et al.  NBP is the p53 homolog p63. , 2001, Carcinogenesis.

[6]  W. Hong,et al.  Visualization of the timing of gene amplification during multistep head and neck tumorigenesis. , 2000, Cancer research.

[7]  P. Hall,et al.  The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. , 2000, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[8]  H. K. Williams.  Molecular pathogenesis of oral squamous carcinoma , 2000, Molecular pathology : MP.

[9]  P. Hall,et al.  Characterization of the expression pattern of p63α and δnp63α in benign and malignant oral epithelial lesions , 2000 .

[10]  L. Sellmann,et al.  Prognostic Significance of p53/bcl‐2 Co‐expression in Patients With Laryngeal Squamous Cell Carcinoma , 2000, The Laryngoscope.

[11]  T. Crook,et al.  High level expression of ΔN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? , 2000, Oncogene.

[12]  M. Leelakriangsak,et al.  Alterations of p53, pRb, cyclin D(1) and cdk4 in human oral and pharyngeal squamous cell carcinomas. , 2000, Oral oncology.

[13]  K. Chang,et al.  Overexpression of p53 in squamous cell carcinoma of the tongue in young patients with no known risk factors is not associated with mutations in exons 5–9 , 2000, Head & neck.

[14]  W. Kaelin,et al.  p63 and p73: old members of a new family. , 2000, Biochimica et biophysica acta.

[15]  J. Jen,et al.  AIS is an oncogene amplified in squamous cell carcinoma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. Yang,et al.  Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. , 2000, Carcinogenesis.

[17]  A. Yang,et al.  p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours , 2000, Nature.

[18]  B. Leggett,et al.  p73 Is up‐regulated in a subset of hepatocellular carcinomas , 2000, Hepatology.

[19]  G. Bradley,et al.  p53 gene mutations in sequential oral epithelial dysplasias and squamous cell carcinomas , 2000, The Journal of pathology.

[20]  F. Carey,et al.  Expression of the p53 homologue p63alpha and deltaNp63alpha in normal and neoplastic cells. , 2000, Carcinogenesis.

[21]  W. Kaelin.  The p53 gene family , 1999, Oncogene.

[22]  F. McKeon,et al.  Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. , 1999, The Journal of investigative dermatology.

[23]  C. Harris,et al.  Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. , 1999, Cancer research.

[24]  G. Chenevix-Trench,et al.  Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target , 1999, Oncogene.

[25]  K. Engeland,et al.  Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. , 1999, Journal of the National Cancer Institute.

[26]  Y. Ishikawa,et al.  The expression of p73 is increased in lung cancer, independent of p53 gene alteration , 1999, British Journal of Cancer.

[27]  K. Engeland,et al.  Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver , 1999, British Journal of Cancer.

[28]  H. Vogel,et al.  p63 is a p53 homologue required for limb and epidermal morphogenesis , 1999, Nature.

[29]  Wei Ding,et al.  Role of p53 gene mutations in human esophageal carcinogenesis: results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions. , 1999, Carcinogenesis.

[30]  A. Sakurada,et al.  Infrequent somatic mutations of the p73 gene in various human cancers. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[31]  D. Tindall,et al.  Overexpression of the wild type p73 gene in human bladder cancer , 1999, Oncogene.

[32]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[33]  H. Kato,et al.  A second p53-related protein, p73L, with high homology to p73. , 1998, Biochemical and biophysical research communications.

[34]  J. Jen,et al.  A new human p53 homologue , 1998, Nature Medicine.

[35]  Chikashi Ishioka,et al.  Cloning and functional analysis of human p51, which structurally and functionally resembles p53 , 1998, Nature Medicine.

[36]  D. Tindall,et al.  Activation of p73 silent allele in lung cancer. , 1998, Cancer research.

[37]  G. Snow,et al.  p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma , 1998, The Journal of pathology.

[38]  C. Brambilla,et al.  Implications of p53 alterations and anti-p53 antibody response in head and neck squamous cell carcinomas. , 1998, Oral oncology.

[39]  Jennifer Kushner,et al.  Patterns of p53 and Ki‐67 protein expression in epithelial dysplasia from the floor of the mouth , 1997, The Journal of pathology.

[40]  S. Dickman.  First p53 Relative May Be a New Tumor Suppressor , 1997, Science.

[41]  W. Kaelin,et al.  p73 is a human p53-related protein that can induce apoptosis , 1997, Nature.

[42]  M. Oren.  Lonely No More: p53 Finds Its Kin in a Tumor Suppressor Haven , 1997, Cell.

[43]  C. Bamberger,et al.  A novel protein with strong homology to the tumor suppressor p53 , 1997, Oncogene.

[44]  A. Yang,et al.  Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.

[45]  T. Nakajima,et al.  The overexpression of p53 and proliferative activity in precancerous and cancerous lesions of oral squamous epithelium. , 1997, Journal of experimental & clinical cancer research : CR.

[46]  S. Lippman,et al.  p53 Expression: Predicting Recurrence and Second Primary Tumors in Head and Neck Squamous Cell Carcinoma , 1996 .

[47]  W. Hong,et al.  Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis , 1996, Cancer and Metastasis Reviews.

[48]  E. Campo,et al.  p53 expression in normal, dysplastic, and neoplastic laryngeal epithelium. Absence of a correlation with prognostic factors , 1995, The Journal of pathology.

[49]  J. S. Giansanti.  Histological typing of oral and oropharyngeal tumors , 1972 .

[50]  J. Piffkó,et al.  Immunophenotypic analysis of normal mucosa and squamous cell carcinoma of the oral cavity. , 1999, Cancer Detection and Prevention.

[51]  J. Regezi,et al.  Expression of p21/waf1 in oral squamous cell carcinomas--correlation with p53 and mdm2 and cellular proliferation index. , 1999, Oral oncology.